» Articles » PMID: 29996667

Epidemiology of Migraine in Men: Results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study

Overview
Journal Cephalalgia
Specialties Neurology
Psychiatry
Date 2018 Jul 13
PMID 29996667
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To assess migraine epidemiology in men by examining gender differences in disease presentation, comorbidities, and prognosis.

Patients And Methods: The Chronic Migraine Epidemiology and Outcomes (CaMEO) Study is a longitudinal survey of US adults with migraine identified by web questionnaire. Data were stratified by gender, collected between September 2012-November 2013, and included sociodemographics, headache features, Migraine Disability Assessment, Migraine Symptom Severity Score, Allodynia Symptom Checklist, and comorbidities. Discrete time hazard models addressed 1-year likelihood of transition from episodic to chronic migraine headache frequency.

Results: Of the 16,789 migraine respondents, 4294 were men (25.6%). Compared to women, men were slightly older at onset of their headaches (mean 24.1 vs. 22.3 years) and had fewer headache days/month (4.3 vs. 5.3 days), slightly less severe attacks (Migraine Symptom Severity Score, 21.6 vs. 22.6), reduced frequencies of grade IV Migraine Disability Assessment scores (15.7% vs. 24.1%), allodynia (32.6% vs. 49.7%), chronic migraine (6.5% vs. 9.6%, each p < 0.001), and common comorbidities. Men were less likely to report consulting a doctor for their headaches and receiving a migraine diagnosis if they consulted. Men and women with episodic migraine had similar crude 1-year risk of chronic migraine onset. Controlling for known risk factors (i.e. depression, headache frequency, allodynia), men had greater likelihood of chronic migraine onset at 6, 9, and 12 months (each p < 0.05).

Conclusions: Findings confirmed gender differences. Men with migraine generally have less severe attacks and disability and are less likely to receive a diagnosis than women with migraine. Prognostic factors may be better understood for women than men.

Citing Articles

Migraine in men.

Fitzek M, Boucherie D, de Vries T, Handtmann C, Fathi H, Raffaelli B J Headache Pain. 2025; 26(1):3.

PMID: 39754046 PMC: 11697684. DOI: 10.1186/s10194-024-01936-7.


Patients' Experiences During the Long Journey Before Initiating Migraine Prevention with a Calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibody (mAb).

Seng E, Lampl C, Viktrup L, Lenderking W, Karn H, Hoyt M Pain Ther. 2024; 13(6):1589-1615.

PMID: 39298053 PMC: 11543966. DOI: 10.1007/s40122-024-00652-z.


Sex-Specific Association of Cardiovascular Risk Factors With Migraine: The Population-Based Rotterdam Study.

Al-Hassany L, Acarsoy C, Ikram M, Bos D, MaassenVanDenBrink A Neurology. 2024; 103(4):e209700.

PMID: 39083723 PMC: 11319068. DOI: 10.1212/WNL.0000000000209700.


Independent causal effect of migraines on Alzheimer's disease risk: a multivariate Mendelian randomization study.

Xu C, Wu W, Fan Y, Zhu S Front Neurol. 2024; 15:1401880.

PMID: 38903170 PMC: 11188460. DOI: 10.3389/fneur.2024.1401880.


Sex differences in the clinical manifestations related to dependence behaviors in medication-overuse headache.

Wang Y, Tzeng Y, Yu C, Ling Y, Chen S, Lai K J Headache Pain. 2023; 24(1):145.

PMID: 37907887 PMC: 10619252. DOI: 10.1186/s10194-023-01685-z.